Search clinical trials for: Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa

Total 57 results

German Breast Group
Bristol-Myers Squibb; Pharmacia; Amgen

Completed

Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)

Breast Cancer
Tao OUYANG

Completed

Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer

Breast Cancer

China
German Breast Group

Completed

Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast (ICE-II)

Breast Cancer

Germany
Heinrich-Heine University, Duesseldorf

Unknown

Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer

Breast Cancer

Germany
Sheffield Teaching Hospitals NHS Foundation Trust

Completed

Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer (ANZAC)

Breast Cancer

United Kingdom
NSABP Foundation Inc
National Cancer Institute (NCI)

Completed

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

Breast Cancer

United States, Canada, Puerto Rico
Henrik Lindman
Scandinavian Breast Group; Danish Breast Cancer Cooperative Group; Swedish Breast... and other collaborators

Completed

Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer

Breast Cancer
Spanish Breast Cancer Research Group
Bristol-Myers Squibb; Pfizer; Hoffmann-La Roche

Completed

Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Breast Cancer

Spain
Technical University of Munich

Completed

Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction (MEMORI)

Adenocarcinoma of the Esophagogastric Junction

Germany
M.D. Anderson Cancer Center
GlaxoSmithKline

Terminated

Phase II Neoadjuvant in Inflammatory Breast Cancer

Breast Cancer

United States
IRCCS Azienda Ospedaliera Universitaria San Martino...

Completed

Adjuvant FEC Versus EP in Breast Cancer (MIG5) (MIG5)

Breast Cancer | Chemotherapy, Adjuvant

Italy
NCIC Clinical Trials Group
Southwest Oncology Group; Cancer and Leukemia Group B; North Central Cancer Treatment...

Completed

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

Breast Cancer

Canada, United States
Harold J. Burstein, MD, PhD
Massachusetts General Hospital; Dana-Farber Cancer Institute; Beth Israel Deaconess... and other collaborators

Completed

Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer

Breast Cancer | Stage I Breast Cancer | Stage II Breast Cancer

United States
M.D. Anderson Cancer Center
Celgene Corporation; Amgen

Completed

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Breast Cancer

United States
RenJi Hospital

Unknown

Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy

Inflammatory Breast Cancer | Invasive Ductal Breast Cancer | Tubular Breast Cancer | Mucinous Breast Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Novartis

Unknown

Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer

Breast Cancer

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Suspended

Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer

Breast Cancer

China
Shandong Cancer Hospital and Institute

Unknown

Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction (BCSMANC)

Breast Cancer

China
Yale University
Genentech, Inc.

Completed

Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer

Her2-Positive Breast Cancer

United States
M.D. Anderson Cancer Center
Breast Cancer Research Foundation

Completed

Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer

Breast Cancer

United States, Mexico, Peru, Spain
Gruppo Italiano Mammella (GIM)

Completed

Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery

Breast Cancer

Italy
Ottawa Hospital Research Institute

Completed

Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC) (OTT15-04)

Breast Cancer

Canada
M.D. Anderson Cancer Center
Eisai Inc.

Completed

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

Breast Cancer

United States
Hellenic Oncology Research Group
University Hospital of Crete

Completed

Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer

Breast Cancer

Greece
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Pfizer

Completed

Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies

Neoplasms, Advanced

United States
Washington University School of Medicine
Genentech, Inc.

Terminated

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

Breast Neoplasms

United States
National Cancer Institute (NCI)

Completed

A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer

Breast Cancer | Breast Neoplasms

United States
M.D. Anderson Cancer Center

Withdrawn

Molecular Triaging of Newly Diagnosed Breast Cancer

Breast Cancer
Hellenic Oncology Research Group
University Hospital of Crete

Completed

Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer

Breast Cancer

Greece
Fudan University

Completed

Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)

Breast Cancer
Fudan University

Completed

Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)

Primary Breast Cancer
Hellenic Oncology Research Group
University Hospital of Crete

Completed

Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer

Breast Cancer

Greece
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Completed

A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer

Breast Cancer

China
Hoffmann-La Roche
Norwegian Radium Hospital

Completed

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

Breast Cancer

Norway
Merck Sharp & Dohme LLC

Terminated

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Neoplasms
ImmunityBio, Inc.

Withdrawn

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Non Hodgkin Lymphoma
GlaxoSmithKline
Merck Sharp & Dohme LLC

Completed

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

Neoplasms

United States, Australia, Spain, Italy, Japan, Netherlands, Canada, France, China
UNICANCER
AstraZeneca; Fondation ARC

Active, not recruiting

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (SAFIR02_Breast)

Metastatic Breast Cancer

France
West German Study Group
AGO Germany

Completed

4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

Breast Cancer

Germany
Hoffmann-La Roche

Completed

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (BERENICE)

Breast Cancer

United States, Canada, Denmark, France, Italy, Poland, Portugal, Spain, United Kingdom, Norway, Germany, Mexico
Hoffmann-La Roche
Genentech, Inc.; Breast International Group

Active, not recruiting

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY)

Breast Cancer

United States, Belgium, Canada, Australia, Austria, Bulgaria, China, Croatia, Denmark, France, Germany, Guatemala, Hungary, Ireland, Italy, Korea, Republic of, Panama, Slovenia, Spain, Taiwan, United Kingdom, Colombia, Czechia, El Salvador and more
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer

Breast Cancer

Italy
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

Breast Cancer

United States, France, Czechia, Italy, Korea, Republic of, Australia, Belgium, Brazil, Canada, Germany, Guatemala, Hong Kong, Hungary, Panama, Peru, Poland, Spain, Taiwan, United Kingdom, Colombia, Bosnia and Herzegovina, Chile, El... and more
Roswell Park Cancer Institute
National Center for Advancing Translational Sciences (NCATS)

Completed

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Prognostic Stage I Breast Cancer AJCC v8 | Prognostic... and other conditions

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Head and Neck Squamous Cell Carcinoma
ImmunityBio, Inc.

Withdrawn

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Non-small Cell Lung Cancer
ImmunityBio, Inc.

Withdrawn

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Urothelial Carcinoma
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

Leukemia

United States, Canada, Australia, Switzerland, Puerto Rico, Netherlands
GlaxoSmithKline

Terminated

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer (INDUCT)

Neoplasms, Breast

United States, Belgium, United Kingdom, Germany, Russian Federation, Italy, France
ImmunityBio, Inc.

Withdrawn

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Colorectal Cancer

3

Subscribe